LaBarre Michael J.

HALO CTO LaBarre sells 21.7K shares for $1.3M; reduced stake 11.1% over 3 days at $58.10 blended avg vs. $57.70 current.

Michael J. LaBarre, SVP and Chief Technical Officer at Halozyme Therapeutics, executed 6 separate sales totaling 21,697 shares for $1,260,680.74 between February 25–27, 2025, at prices clustered around the blended average of $58.10. This sale reduced his holdings by 11.1% from 195,453 to 173,756 shares. The transaction occurred while the stock trades at $57.70 current price, near the upper end of its 52-week range ($37.81–$64.42) and 10.4% below the 52-week high, suggesting the sales occurred into relative strength. LaBarre's prior 5 trades at HALO show mixed timing outcomes: 3 of 5 were well-timed at the 90-day mark (stock fell after), while 2 showed modest gains, indicating no consistent pattern of prescient selling at this ticker. His cross-ticker track record shows a 90-day well-timed rate of 83.33% with a -14.1% average 90-day return, establishing him as a relatively disciplined seller historically, though that pattern is not ticker-specific. The sale size and blended execution price merit tracking against forthcoming quarterly results, but no material adverse signal is evident in the fundamentals: FY revenue growth stands at 22.4% with a low P/E of 12.79.

HALO CTO Michael LaBarre sells 20,000 shares across 3 transactions for $1,070,058.66; stock now -17.0% from 52-week high.

Michael LaBarre, SVP and Chief Technical Officer at Halozyme, executed 3 separate open-market sales totaling 20,000 shares (20.0K shares) for $1,070,058.66 (blended average $53.50) on October 15–16, 2024, reducing his holdings by 10.3% to 173.8K shares. The sales occurred at prices ranging from $53.26 to $54.24, while the stock has since declined to $53.46 (currently -17.0% from its 52-week high of $64.42 and down -15.0% over the past 30 days). Halozyme's recent fundamentals remain solid—$231.4M in latest quarterly revenue with +25.6% annual growth and a P/E of 20.10—suggesting the stock price movement reflects near-term market sentiment rather than deteriorating business performance. The timing pattern of his prior HALO sales shows no measurable well-timed outcomes at the 90-day mark, and his cross-ticker track record of 9 prior sells averaged a +4.5% 30-day return, neither of which clarifies near-term market direction.

HALO CTO LaBarre sells 20,000 shares across 3 trades (Sept 17-18) at blended $62.45; stock +22.5% in 90 days.

Michael J. LaBarre, SVP and Chief Technical Officer, executed 3 separate sales totaling 20,000 shares for $1,249,095.53 on 2024-09-17 and 2024-09-18, at an average of $62.45 per share. His holdings decreased 10.3% to 173.8K shares post-transaction. The timing context shows HALO stock has climbed 22.5% over the prior 90 days and currently trades at $62.31, near its 52-week high of $64.42. The company's fundamentals remain robust: Revenue $231.4M (latest quarter), net income $93.2M, annual revenue growth +25.6%, and P/E of 23.42. Across his prior 5 trades at HALO dating to late July, Larbarre has sold consistently; subsequent 30-day outcomes on measurable prior sales were positive (July trades: +13.8% and +13.2%), suggesting his prior sales in this window have not preceded declines."

Halozyme CTO LaBarre sells 20,000 shares for $1.2M across 3 transactions as stock nears 52-week high of $62.17.

LaBarre Michael J., SVP and Chief Technical Officer, executed 3 separate sales on August 20–21, 2024, totaling 20,000 shares (20.0K shares) for $1,228,019.90 ($1.2M) at a blended average price of $61.40. The sales reduced his holdings from 188,176 to 168,176 shares (168.2K shares), a -10.6% reduction. The timing is notable: these sales occurred as the stock was appreciating sharply—the current price of $62.17 represents the 52-week high (+0.0% from peak), with 90-day appreciation of +41.6% and 30-day appreciation of +14.4%. His prior 3 trades at HALO (all on 2024-07-23 and 2024-07-24, also sales) have not yet reached measurable 90-day outcomes; his cross-ticker track record shows 3 prior sells but lacks a demonstrated pattern of well-timed sales. The company's fundamentals remain solid: Q-latest revenue of $231,353,000.00 ($231.4M), net income of $93,245,000.00 ($93.2M), annual revenue growth of +25.6%, and a P/E of 23.37.

SVP/CTO Michael J. LaBarre sold 20,000 shares at $55.00 avg price, reducing holdings 10.6% to 168.2K shares.

Michael J. LaBarre, SVP and Chief Technical Officer at HaloZyme, executed 3 separate sales totaling 20,000 shares for $1,100,023.39 on July 23–24, 2024, at a blended average price of $55.00. The stock's 52-week high is $55.40, placing this sale near recent peak levels, and HaloZyme is trading at only -0.4% from that high. At a current price of $55.15 and a market cap of $7,019,161,100.00 with a P/E of 22.06, the company's fundamentals show strong momentum: revenue is $195,879,000.00 in the latest quarter with annual growth of +25.6%, and net income was $76,823,000.00. The stock itself has risen 43.4% over 90 days and 5.9% over 30 days, creating a bullish backdrop for the sale. LaBarre retains 168.2K shares post-transaction, indicating substantial continued position ownership.